Advances and Prospects in Next-Generation CRISPR-Based Cancer Diagnostics CRISPR
01Abstract
The development of CRISPR-based diagnostic technologies has created new opportunities for the sensitive and programmable detection of cancer-associated nucleic acids. By coupling guide-RNA-directed target recognition with collateral cleavage by Cas12 or Cas13 effectors, these platforms convert specific molecular interactions into fluorescent, colorimetric, electrochemical, or lateral-flow signals. When combined with target pre-amplification strategies, CRISPR assays may detect low-abundance mutations and RNA biomarkers in liquid-biopsy specimens. This review provides a concise overview of the molecular principles of CRISPR diagnostics, target recognition mechanisms, amplification strategies and emergent assay formats, with a particular emphasis on Cas12- and Cas13-based systems. Includes the applications of circulating tumor DNA, microRNAs, extracellular vesicles, early detection, tumor profiling, and treatment monitoring. Besides the analytical, pre-analytical, regulatory and implementation barriers currently limiting clinical translation, integrated microfluidic and point-of-care platforms are also discussed. The analytical performance described is promising, but many of the cancer-related assays are still at the proof-of-concept stage and require validation in larger prospective, multicenter cohorts. Before CRISPR-based tests can be used as routine diagnostics, standardized sample processing, reference materials, reproducible assay design and comparisons with established clinical methods will be imperative.
Keywords: cancer diagnostics; circulating tumor DNA; CRISPR-Cas; microRNA; liquid biopsy; Cas12a; Cas13; extracellular vesicles
02Authors
03Article Details
- Section
- Articles Publishing terms and rules
- Pages
- 46-68
- Published
- 2026-10-31
- License
-

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
04References
- 1. Yazdi, Z.F. et al. (2024) “Recent progress in prompt molecular detection of liquid biopsy using Cas enzymes: innovative approaches for cancer diagnosis and analysis,” Journal of Translational Medicine, 22(1), p. 1173. doi:10.1186/s12967-024-05908-y.
- 2. Wang, K. et al. (2023) “Liquid biopsy techniques and pancreatic cancer: diagnosis, monitoring, and evaluation,” Molecular Cancer, 22(1). doi:10.1186/s12943-023-01870-3.
- 3. Rahimi, S. et al. (2024) “CRISPR-Cas target recognition for sensing viral and cancer biomarkers,” Nucleic Acids Research, 52(17), pp. 10040–10067. doi:10.1093/nar/gkae736.
- 4. Dongen, J.E. van and Segerink, L.I. (2025) “Building the Future of Clinical Diagnostics: An Analysis of Potential Benefits and Current Barriers in CRISPR/Cas Diagnostics,” ACS Synthetic Biology, 14(2), pp. 323–331. doi:10.1021/acssynbio.4c00816.
- 5. Wang, M. et al. (2023) “CRISPR applications in cancer diagnosis and treatment,” Cellular & Molecular Biology Letters, 28(1), p. 73. doi:10.1186/s11658-023-00483-4.
- 6. Singh, S. et al. (2022) “Tailored point-of-care biosensors for liquid biopsy in the field of oncology,” Lab on a Chip, 23(1), pp. 44–61. doi:10.1039/d2lc00666a.
- 7. Zhou, Z., Cho, I. and Kadam, U.S. (2025) “CRISPR-Cas-Based Diagnostics in Biomedicine: Principles, Applications, and Future Trajectories,” Biosensors, 15(10), p. 660. doi:10.3390/bios15100660.
- 8. Feng, W. et al. (2021) “CRISPR technology incorporating amplification strategies: molecular assays for nucleic acids, proteins, and small molecules,” Chemical Science, 12(13), pp. 4683–4698. doi:10.1039/d0sc06973f.
- 9. Rossetti, M. et al. (2022) “Enhancement of CRISPR/Cas12a trans-cleavage activity using hairpin DNA reporters,” Nucleic Acids Research, 50(14), pp. 8377–8391. doi:10.1093/nar/gkac578.
- 10. Kaminski, M.M. et al. (2021) “CRISPR-based diagnostics,” Nature Biomedical Engineering, 5(7), pp. 643–656. doi:10.1038/s41551-021-00760-7.
- 11. Huyke, D.A. et al. (2022) “Enzyme Kinetics and Detector Sensitivity Determine Limits of Detection of Amplification-Free CRISPR-Cas12 and CRISPR-Cas13 Diagnostics,” Analytical Chemistry, 94(27), pp. 9826–9834. doi:10.1021/acs.analchem.2c01670.
- 12. Qian, X. et al. (2024) “CRISPR for companion diagnostics in low-resource settings,” Lab on a Chip, 24(20), pp. 4717–4740. doi:10.1039/d4lc00340c.
- 13. Slattery, J.R. et al. (2025) “CRISPR-Powered Liquid Biopsies in Cancer Diagnostics,” Cells, 14(19), p. 1539. doi:10.3390/cells14191539.
- 14. Zhou, Y. et al. (2024) “Tumor biomarkers for diagnosis, prognosis and targeted therapy,” Signal Transduction and Targeted Therapy, 9(1), p. 132. doi:10.1038/s41392-024-01823-2.
- 15. Darbeheshti, F. and Makrigiorgos, G.M. (2023) “Enzymatic Methods for Mutation Detection in Cancer Samples and Liquid Biopsies,” International Journal of Molecular Sciences, 24(2), p. 923. doi:10.3390/ijms24020923.
- 16. Liu, Z. et al. (2024) “Microfluidic biosensors for biomarker detection in body fluids: a key approach for early cancer diagnosis,” Biomarker Research, 12(1), p. 153. doi:10.1186/s40364-024-00697-4.
- 17. Sarhadi, V.K. and Armengol, G. (2022) “Molecular Biomarkers in Cancer,” Biomolecules, 12(8), p. 1021. doi:10.3390/biom12081021.
- 18. Palaz, F. et al. (2021) “CRISPR-Cas13 System as a Promising and Versatile Tool for Cancer Diagnosis, Therapy, and Research,” ACS Synthetic Biology, 10(6), pp. 1245–1267. doi:10.1021/acssynbio.1c00107.
- 19. Hong, J. et al. (2023) “CRISPR/Cas13a‐Based MicroRNA Detection in Tumor‐Derived Extracellular Vesicles,” Advanced Science, 10(24). doi:10.1002/advs.202301766.
- 20. Liu, Yin et al. (2021) “EasyCatch, a convenient, sensitive and specific CRISPR detection system for cancer gene mutations,” Molecular Cancer, 20(1), p. 157. doi:10.1186/s12943-021-01456-x.
- 21. Tenchov, R. et al. (2024) “Biomarkers for Early Cancer Detection: A Landscape View of Recent Advancements, Spotlighting Pancreatic and Liver Cancers,” ACS Pharmacology & Translational Science, 7(3), pp. 586–613. doi:10.1021/acsptsci.3c00346.
- 22. Yu, D. et al. (2022) “Exosomes as a new frontier of cancer liquid biopsy,” Molecular Cancer, 21(1), p. 56. doi:10.1186/s12943-022-01509-9.
- 23. Ma, L. et al. (2024) “Liquid biopsy in cancer: current status, challenges and future prospects,” Signal Transduction and Targeted Therapy, 9(1), p. 336. doi:10.1038/s41392-024-02021-w.
- 24. Nikanjam, M., Kato, S. and Kurzrock, R. (2022) “Liquid biopsy: current technology and clinical applications,” Journal of Hematology & Oncology, 15(1), p. 131. doi:10.1186/s13045-022-01351-y.
- 25. Ghosh, S. et al. (2024) “Harnessing exosomes as cancer biomarkers in clinical oncology,” Cancer Cell International, 24(1), p. 278. doi:10.1186/s12935-024-03464-5.
- 26. Salmond, N. and Williams, K.C. (2021) “Isolation and characterization of extracellular vesicles for clinical applications in cancer – time for standardization,” Nanoscale Advances, 3(7), pp. 1830–1852. doi:10.1039/d0na00676a.
- 27. Moding, E.J. et al. (2021) “Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease,” Cancer Discovery, 11(12), pp. 2968–2986. doi:10.1158/2159-8290.cd-21-0634.
- 28. Passaro, A. et al. (2024) “Cancer biomarkers: Emerging trends and clinical implications for personalized treatment,” Cell, 187(7), pp. 1617–1635. doi: 10.1016/j.cell.2024.02.041.
- 29. Deveson, I.W. et al. (2021) “Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology,” Nature Biotechnology, 39(9), pp. 1115–1128. doi:10.1038/s41587-021-00857-z.
- 30. Dasari, A. et al. (2020) “ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper,” Nature Reviews Clinical Oncology, 17(12), pp. 757–770. doi:10.1038/s41571-020-0392-0.
- 31. Tivey, A. et al. (2022) “Circulating tumour DNA — looking beyond the blood,” Nature Reviews Clinical Oncology, 19(9), pp. 600–612. doi:10.1038/s41571-022-00660-y.
- 32. Ntzifa, A. and Lianidou, E. (2023) “Pre-analytical conditions and implementation of quality control steps in liquid biopsy analysis,” Critical Reviews in Clinical Laboratory Sciences, 60(8), pp. 573–594. doi:10.1080/10408363.2023.2230290.
- 33. Williams, P.M. et al. (2021) “Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health,” JCO Precision Oncology, 5(5), pp. 910–920. doi:10.1200/po.20.00528.
